Washington-based synthetic biology platform AbSci has entered into a USD 610 million research collaboration with Merck (known as MSD outside the United States and Canada) to discover and develop novel therapeutics across undisclosed therapeutic areas.
The duo will research three targets by leveraging AbSci’s synthetic biology and AI-powered integrated drug creation platform; Merck has the option to progress the targets by entering into a drug discovery collaboration agreement afterward. The partnership will also leverage AbSci’s non-standard amino acid technology to develop enzymes specific to Merck’s biomanufacturing applications.
AbSci will receive a total of USD 610 million consisting of an upfront payment, milestone payments, tiered royalties on sales, and research funding. A breakdown of how the payments will be received was not disclosed.
Analyst QuickTake: Merck and AbSci have already been involved since February 2021 via a strategic investment of around USD 5 million from the Merck Global Health Innovation Fund (Merck GHI) to support the development of AbSci’s deep learning platform Denovium Engine. The company’s share price hiked by 17% with the latest collaboration, indicating an increase in investor confidence, partially recovering its slumped share price since its IPO in July 2021 .
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.